Cardiovascular disease Archives

News and Trends 6 Oct 2022

Novartis Biome UK Heart Health Catalyst 2022 winners announced

Novartis Pharmaceuticals UK has announced that Xim, creators of Lifelight, and PocDoc are the successful companies of the Novartis Biome UK Heart Health Catalyst 2022, in partnership with Medtronic, RYSE…

October 6, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 22 Sep 2022

Rivus Pharmaceuticals raises $132M for treatment of obesity and cardio-metabolic disorders

Rivus Pharmaceuticals Inc. has completed a $132 million series B financing round. It was led by RA Capital Management with participation from Bain Capital Life Sciences, BB Biotech AG and…

September 22, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 12 Sep 2022

Cuffless device worn 24/7 can lower blood pressure, says Aktiia

A company making cuffless monitors for blood pressure says a significant and sustained reduction has been achieved for patients wearing the monitor 24/7. The device, made by Aktiia, measures blood…

September 12, 2022 - 2 minutesmins - By Liza Laws

News and Trends 22 Aug 2022

Vaderis emerges from stealth to start HTT trial

Vaderis Therapeutics AG, a clinical stage biotech company focused on developing treatments for rare diseases associated with vascular malformations, has emerged from stealth. The company has also started its INSIGHT…

August 22, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 2 Nov 2017

AstraZeneca and Moderna want to beat Novartis at Treating Heart Failure

AstraZeneca will work with Moderna Therapeutics to bring together to the market an mRNA version of Novartis' failed heart failure drug Serelaxin. AstraZeneca has signed a deal with US biotech Moderna Therapeutics to co-develop and co-commercialize…

November 2, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 13 Jul 2022

Sanofi sells two portfolios of established products to Neuraxpharma

Two drugs portfolios with products to treat the central nervous system, pain and vascular disease have been bought by pharmaceutical company, Neuraxpharm Group. The company bought the portfolios from…

July 13, 2022 - 2 minutesmins - By Liza Laws

News and Trends 5 Jul 2022

Novartis Pharmaceuticals UK launches health-tech investor partnership for cardiovascular care

Novartis Pharmaceuticals UK has launched the Novartis Biome UK Heart Health Catalyst 2022, in a world-first investor partnership with Medtronic ltd, RYSE Asset Management, and Chelsea and Westminster Hospital NHS…

July 5, 2022 - 4 minutesmins - By Jim Cornall

News and Trends 30 Jun 2022

Acticor Biotech gets patent for cardiovascular emergency treatment product

French company Acticor Biotech has announced the European Patent Office (EPO) has granted a new patent that provides protection for the use of Acticor’s product, glenzocimab in thrombotic diseases in…

June 30, 2022 - 2 minutesmins - By Jim Cornall

diabetes chronic kidney disease farxiga astraZeneca

News and Trends 8 Jun 2021

Farxiga’s Approval Fuels Chronic Kidney Disease Comeback

Until this year, there were no effective treatments for chronic kidney disease. However, the recent approval of AstraZeneca’s Farxiga alongside clinical breakthroughs and advances in precision medicine are causing the…

June 8, 2021 - 5 minutesmins - By Jonathan Smith

cardiovascular disease amarin vascepa vazkepa

News and Trends 21 Apr 2021

Vazkepa Gets EMA Nod for Cardiovascular Disease, But Hurdles Remain

Last month’s EU approval of Vazkepa -- a treatment derived from fish oil and branded as Vascepa in the US -- has added much-needed ammunition to the arsenal of doctors…

April 21, 2021 - 5 minutesmins - By Victor Kotsev

News and Trends 1 Feb 2020

Cardior Pharmaceuticals’ Heart Failure Drug Shows Curative Potential

German biotech company Cardior Pharmaceuticals’ candidate heart failure drug has the potential to stop the condition in its tracks, according to early studies in animal models. At present, treatments for…

February 1, 2020 - 3 minutesmins - By Jonathan Smith

News and Trends 16 Dec 2019

Amarin’s Triglyceride-Lowering Drug Gets Second FDA Nod to Tackle Cardiovascular Disease

A treatment developed by the Irish company Amarin has become the first FDA-approved drug to lower the risk of strokes and heart attacks when combined with statins in patients with…

December 16, 2019 - 2 minutesmins - By Jonathan Smith

Report: new Frontiers in Vaccinology

Listen to our podcast

View all sectors A-Z

Power your event with partnering to deliver attendee ROI. Learn more!

View all companies A-Z

Partner with world-leading academics working on sustainable materials R&D

View all countries A-Z

Report: The European Biotech Startup Ecosystem

Subcribe to our newsletter

Learn more about Inpart, the leading platform for biopharma partnering